Valiant Organics Ltd

- No new long-term borrowings are planned for the near future. - The company expects to fund its CAPEX internally without raising new debt. - Some short-term loans for working capital may fluctuate, but no major increase in debt expected. - Debt to equity ratio is currently comfortable at about 25%. - Management aims to reduce short-term loans as working capital requirements normalize. - No mention of any planned equity fundraising in the call.

- For FY23, the planned CAPEX is around Rs. 60-70 crores. - Major portion allocated for Ahmedabad plant redevelopment. - Additional CAPEX for pharma intermediates expansion and moving PAP (para-aminophenol) production to continuous processing. - The continuous process at PAP will require further CAPEX as part of scaling up production. - The pharma intermediates project has incurred about Rs. 55 crores out of a Rs. 60 crore budget but is not yet commercialized. - OAP (ortho-aminophenol) project, with a budget around Rs. 30 crores, is also in progress but not yet commercialized. - Continuous process for PAP aims to increase production capacity beyond the current batch process limit of 500 tons/month. - No major new large ticket investments are planned until stabilization of ongoing projects.

- FY23 volume expected around 60,000-65,000 tons, up from ~50,000 tons (Page 14-15). - Hydrogenation volumes (including PAP and OAP) to increase, with PAP ramping from 300 to 500 tons/month in H1 FY23 and targeted 1000 tons/month by end of FY23 (Pages 14, 18-19). - Continuous process at PAP expected to improve margins and volumes further beyond 500 tons/month (Page 19). - Sales guidance: FY23 standalone revenue target ~1200-1250 crores; FY24 target ~1400 crores (Page 18). - EBITDA margin expected to improve to around 15% at 500 tons/month PAP volume and higher with continuous process (Page 19). - Revenue growth guidance: 35-40% growth next year (FY23), followed by 15-20% growth in the subsequent year (Page 18). - New products OAP and pharma intermediates expected to start contributing from Q2 FY23, supporting volume growth (Page 8).

- Expecting revenue growth of around 35-40% for FY23 and 15-20% growth for FY24 on a standalone basis. - Projected volumes: 1200-1250 tons in FY23 and approximately 1400 tons in FY24. - EBITDA margin guidance around 15-16% achievable at 500-600 tons/month PAP volume, improving further with continuous processing. - Anticipated gross margin stabilization near 30%, with EBITDA margin around 20-22% on a normalized basis post market stabilization. - Operating efficiency expected to improve with full scaling of PAP production and commencement of continuous processing. - CAPEX of Rs. 60-70 crores planned for FY23 aimed at Ahmedabad redevelopment, pharma intermediates, and PAP continuous process expansion. - Long-term debt expected to reduce from Rs. 128 crores to around Rs. 90-95 crores by end of next year, improving financial stability.

The provided pages of the Valient Organics Limited earnings call transcript do not mention any details about the current or expected order book or pending orders. The discussion mainly focuses on production volumes, margins, CAPEX, debt, and operational efficiencies. Therefore, no specific information regarding order book or pending orders is available in the provided document excerpt. If you would like, I can assist you in locating that information if provided in other parts of the document.